What is Leerink Partnrs’ Estimate for BOLT Q1 Earnings?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Research analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Bolt Biotherapeutics in a report issued on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings of ($0.36) per share for the quarter. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS and Q4 2026 earnings at ($0.16) EPS.

Several other research firms have also issued reports on BOLT. HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Tuesday. Stifel Nicolaus lowered their price target on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Stock Down 0.1 %

BOLT stock opened at $0.44 on Thursday. The firm’s fifty day moving average is $0.47 and its 200 day moving average is $0.55. The firm has a market cap of $16.82 million, a PE ratio of -0.26 and a beta of 0.94. Bolt Biotherapeutics has a one year low of $0.38 and a one year high of $1.56. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.79 million.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC purchased a new position in Bolt Biotherapeutics in the 4th quarter valued at approximately $42,000. Velan Capital Investment Management LP purchased a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at about $27,000. Squarepoint Ops LLC acquired a new position in shares of Bolt Biotherapeutics during the fourth quarter worth about $26,000. Millennium Management LLC purchased a new stake in shares of Bolt Biotherapeutics during the fourth quarter worth approximately $25,000. Finally, FMR LLC increased its stake in shares of Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares during the period. 86.70% of the stock is currently owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.